ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 135 filers reported holding ROYALTY PHARMA PLC in Q3 2020. The put-call ratio across all filers is 1.34 and the average weighting 0.7%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $19,536,647 | +5.4% | 719,847 | +19.4% | 0.00% | +33.3% |
Q2 2023 | $18,534,345 | -8.7% | 602,939 | +7.0% | 0.00% | -25.0% |
Q1 2023 | $20,307,805 | -10.4% | 563,636 | -1.7% | 0.00% | -33.3% |
Q4 2022 | $22,661,954 | -35.6% | 573,430 | -34.5% | 0.01% | -33.3% |
Q3 2022 | $35,197,000 | +4.7% | 876,000 | +9.5% | 0.01% | +12.5% |
Q2 2022 | $33,624,000 | +141.5% | 799,800 | +123.8% | 0.01% | +300.0% |
Q1 2022 | $13,925,000 | -48.2% | 357,400 | -47.0% | 0.00% | +100.0% |
Q4 2021 | $26,868,000 | +180.4% | 674,192 | +154.3% | 0.00% | -50.0% |
Q3 2021 | $9,581,000 | -44.8% | 265,100 | -37.4% | 0.00% | -33.3% |
Q2 2021 | $17,361,000 | -45.2% | 423,527 | -41.7% | 0.00% | -40.0% |
Q1 2021 | $31,665,000 | +3.4% | 725,920 | +18.6% | 0.01% | +150.0% |
Q4 2020 | $30,636,000 | +165.7% | 612,106 | +123.3% | 0.00% | -33.3% |
Q3 2020 | $11,531,000 | +244.1% | 274,108 | +297.2% | 0.00% | – |
Q2 2020 | $3,351,000 | – | 69,013 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
Brown University | 381,759 | $19,107,000 | 13.82% |
Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |